KIT D816V Mutation Analysis
Allele-specific PCR detection of the KIT D816V mutation in core-binding factor AML and mastocytosis.
KMT2A::MLLT3 (MLL::AF9) t(9;11)
Quantitative RT-PCR detection of KMT2A::MLLT3 fusion transcripts from the t(9;11) translocation.
NPM1 Mutation Analysis
PCR fragment analysis of common 4 bp insertion mutations in NPM1 exon 12 for AML diagnosis.
WT1 Gene Transcript Levels by RT-PCR
Quantitative RT-PCR determination of Wilms' Tumor (WT1) transcript levels for MDS and AML monitoring.
KMT2A::AFDN t(6;11) (aka KMT2A::MLLT4 or MLL::AF6)
Quantitative RT-PCR detection of KMT2A::AFDN fusion transcripts from t(6;11) involving the 11q23 KMT2A locus.
BCR::ABL1 IS t(9;22)
Quantitative RT-PCR detection and monitoring of the t(9;22) BCR::ABL1 fusion transcript (p210 and p190) for CML, ALL, and AML diagnosis and MRD.
BCR::ABL1 Qualitative Breakpoints p190 vs p210
Qualitative RT-PCR identification of BCR::ABL1 fusion transcript breakpoint type (major p210 vs minor p190) for diagnosis of CML, ALL, and AML.
ABL1 Tyrosine Kinase Domain Mutation Analysis
Sanger sequencing of ABL1 tyrosine kinase domain to detect imatinib resistance mutations in BCR::ABL1-positive CML, ALL, and AML.
KMT2A::MLLT11 (MLL::AF1) t(1;11)
Quantitative RT-PCR detection of KMT2A::MLLT11 fusion transcripts from the t(1;11) translocation.
CBFB::MYH11 inv(16) or t(16;16)
Quantitative RT-PCR detection and monitoring of CBFB::MYH11 fusion transcripts (types A, D, E) from inv(16)/t(16;16) in AML.
